Compare BABA & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BABA | JNJ |
|---|---|---|
| Founded | 1999 | 1886 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 423.5B | 449.6B |
| IPO Year | 2014 | 1944 |
| Metric | BABA | JNJ |
|---|---|---|
| Price | $157.46 | $205.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $189.08 | ★ $196.60 |
| AVG Volume (30 Days) | ★ 14.7M | 9.1M |
| Earning Date | 11-25-2025 | 10-14-2025 |
| Dividend Yield | 0.67% | ★ 2.51% |
| EPS Growth | 51.05 | ★ 71.26 |
| EPS | 7.35 | ★ 10.35 |
| Revenue | ★ $142,158,529,239.00 | $92,149,000,000.00 |
| Revenue This Year | $6.00 | $6.62 |
| Revenue Next Year | $11.49 | $5.28 |
| P/E Ratio | $21.41 | ★ $20.00 |
| Revenue Growth | ★ 5.21 | 5.08 |
| 52 Week Low | $80.06 | $140.68 |
| 52 Week High | $192.67 | $207.81 |
| Indicator | BABA | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 78.27 |
| Support Level | $150.00 | $185.12 |
| Resistance Level | $166.37 | $207.81 |
| Average True Range (ATR) | 6.13 | 3.20 |
| MACD | -0.24 | 1.02 |
| Stochastic Oscillator | 45.09 | 93.37 |
Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China retail e-commerce platform is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China wholesale e-commerce, international retail and wholesale e-commerce, local consumer services, travel services, cloud computing, digital media and entertainment, Cainiao logistics services, and other businesses.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.